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Background: It remains unknown whether desaturation profiles during daily living are associated with prognosis in
patients with chronic obstructive pulmonary disease (COPD). Point measurements of resting oxygen saturation by
pulse oximetry (SpO2) and partial pressure of arterial oxygen (PaO2) are not sufficient for assessment of desaturation
during activities of daily living. A small number of studies continuously monitored oxygen saturation throughout
the day during activities of daily living in stable COPD patients. This study aims to analyse the frequency of
desaturation in COPD outpatients, and investigate whether the desaturation profile predicts the risk of exacerbation.
Methods: We studied stable COPD outpatients not receiving supplemental oxygen therapy. Baseline assessments
included clinical assessment, respiratory function testing, arterial blood gas analysis, body mass index, and the
COPD Assessment Test (CAT). Patients underwent 24-hour ambulatory monitoring of SpO2 during activities of daily
living. Exacerbations of COPD and death from any cause were recorded.
Results: Fifty-one patients were enrolled in the study, including 12 current smokers who were excluded from the
analyses in case high serum carboxyhaemoglobin concentrations resulted in inaccurately high SpO2 readings. The
mean percent predicted forced expiratory volume in one second (%FEV1) was 50.9%. The mean proportion of SpO2
values below 90% was 3.0% during the day and 7.4% during the night. There were no daytime desaturators,
defined as ≥ 30% of daytime SpO2 values below 90%. Twenty-one exacerbations occurred in 13 patients during the
mean follow-up period of 26.4 months. Univariate and multivariate Cox proportional hazards analyses did not detect
any significant factors associated with exacerbation.
Conclusions: Our 24-hour ambulatory oximetry monitoring provided precise data regarding the desaturation
profiles of COPD outpatients. Both daytime and nighttime desaturations were infrequent. The proportion of
ambulatory SpO2 values below 90% was not a significant predictor of exacerbation.
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Chronic obstructive pulmonary disease (COPD) is a lead-
ing cause of morbidity and disability worldwide, and is
predicted to become the third highest cause of death by
2020 [1]. Desaturation profiles during a 6-minute walk test
(6MWT) may predict prognosis primarily in patients with
severe COPD with a percent predicted forced expiratory
volume in one second (FEV1) of < 50% [2]. Time to desat-
uration during a 6MWTalso predicts desaturation time in
24-hour ambulatory oximetry monitoring primarily in
moderately hypoxaemic COPD patients with a resting
partial pressure of arterial oxygen (PaO2) between 60 and
70 mmHg [3]. However, it remains unknown whether de-
saturation profiles measured by ambulatory oximetry can
predict prognosis in COPD patients. Transient desatura-
tions have been observed in patients with moderate to
severe chronic pulmonary disorders, even without signifi-
cant resting hypoxemia [4]. Point measurements of resting
oxygen saturation by pulse oximetry (SpO2) and PaO2, the
conventional parameters used to determine requirements
of long-term oxygen therapy, are not sufficient for assess-
ment of desaturation during activities of daily living [5].
Field walking tests such as the 6MWT, which is the stand-
ard test used for assessment of functional exercise toler-
ance, do not always provide a good reflection of variations
in oxygen saturation, because most activities of daily living
are performed at submaximal levels of effort. 6MWT re-
sults did not predict the degree of desaturation during
defecation in patients with chronic respiratory failure [6].
Conventional assessment methods are therefore not satis-
factory for obtaining a comprehensive understanding of
oxygen saturation throughout the day.
Pulse oximetry is a rapid, non-invasive method of moni-
toring the oxygen saturation of haemoglobin. Recent
technological advances have enabled development of low-
cost, small, user-friendly, portable pulse oximeters that
can record data for over 24 hours. Many studies have
evaluated the usefulness of pulse oximetry in COPD
patients, but most studies only monitored patients con-
tinuously during the night or for a short period during
the day. Although several studies monitored patients
continuously during the day, most of these included
patients with severe COPD on long-term oxygen ther-
apy, or exclusively analysed patients on long-term oxy-
gen therapy.
This study aimed to evaluate the desaturation profiles
of Japanese COPD outpatients not receiving supplemental
oxygen therapy during activities of daily living at home
using continuous 24-hour pulse oximetry monitoring, and
analyse the frequency of desaturation and relationships
between the desaturation profile and the clinical charac-
teristics and risk of exacerbation. The ability of the
desaturation profile to predict exacerbation of COPD
was investigated.Methods
Patient selection
Patients were recruited from the outpatient clinic in the
Department of Respiratory Medicine at Osaka Police
Hospital. The inclusion criteria were: (1) clinically stable
COPD according to the Global Initiative on Obstructive
Lung Disease guidelines, with a FEV1 to forced vital
capacity ratio of < 70% and minimal or no reversibility
to β2-agonists (<200 mL and/or < 15%); (2) able to walk
independently or with a cane; and (3) sufficient cogni-
tive function to follow the instructions for using the
pulse oximeter. Patients were excluded if they were cur-
rently hospitalised, if they had experienced an exacerbation
requiring hospitalisation or administration of antibiotics or
steroids during the preceding 3 months, if they had other
significant respiratory diseases or medical problems that
precluded ambulatory activities at home, and if they were
receiving supplemental oxygen therapy.
Experimental design
Within 1 month of ambulatory oximetry monitoring, all
patients underwent spirometry, arterial blood gas analysis,
assessment of the modified Medical Research Council
(mMRC) dyspnoea scale score, and the Japanese version
of the COPD assessment test (CAT) (GlaxoSmithKline;
http://www.catestonline.org/) [7,8]. Spirometry was per-
formed using an autospirometer (Autospirometer System
7; Minato Medical Science, Osaka, Japan) according to the
American Thoracic Society guidelines. Samples for arterial
blood gas analysis were obtained from the radial artery
with the patient resting in the sitting position and breath-
ing room air, and PaO2 and partial pressure of arterial
carbon dioxide (PaCO2) were immediately measured using
a blood gas analyser (RAPIDPoint 405 Arterial Blood Gas
Analyzer; Siemens Healthcare Diagnostics Inc., Tarrytown,
NY, USA).
A portable pulse oximeter (PULSOX-Me300; Konica-
Minolta, Tokyo, Japan) was used to obtain continuous
oximetry data over a 24-hour period. SpO2 and the pulse-
rate waveform were recorded every second. A nurse indi-
vidually instructed each patient on the proper use of the
portable oximeter before the start of monitoring. The
finger probe of the portable oximeter was positioned on
the patient’s non-dominant hand to minimise interference
during normal daily activities. The portable oximeter was
attached to the patient’s wrist during the monitoring
period. Periods during which the heart rate fell abruptly
by ≥ 25 beats/minute were excluded from the analyses. All
data were downloaded to a computer for analysis (DS-Me
version 2.10). A calibration check according to the manu-
facturer’s instructions was performed before and after use.
Patients were instructed to keep an activity log to record
the times of major daily activities (sleeping, eating, walking
outdoors, bathing, and other physical activities). Based on
Table 1 Baseline characteristics of ex-/non-smokers
(n = 39)
Age (years) Mean ± SD 71.6 ± 8.8
Sex Male/female 36/3
Smoking pack/years Mean ± SD 68.2 ± 33.4
BMI (kg/m2) Mean ± SD 23.1 ± 3.8
Underweight (BMI < 18.5 kg/m2) n (%) 4 (10.3)
Overweight (BMI 25–30 kg/m2) n (%) 5 (12.8)
Obese (BMI≥ 30 kg/m2) n (%) 2 (5.1)
Unadjusted Charlson Comorbidity
Index
Median (range) 1 (0–4)
Age-adjusted Charlson Comorbidity
Index
Median (range) 5 (2–9)
Treatment
Long-acting muscarinic antagonist n (%) 26 (67%)
Long-acting β2 agonist n (%) 27 (69%)
Inhaled corticosteroid n (%) 27 (69%)
PaO2 (mmHg) Mean ± SD 78.2 ± 8.9
PaCO2 (mmHg) Mean ± SD 39.1 ± 4.9
GOLD stage I/II/III/IV 2/18/13/6
FEV1 (L) Mean ± SD 1.3 ± 0.6
FEV1 (%predicted) Mean ± SD 50.9 ± 18.5
FVC (L) Mean ± SD 2.3 ± 1.0
mMRC dyspnoea grade Mean ± SD 2.2 ± 1.1
Median (range) 2 (0–4)
CAT score Mean ± SD 11.7 ± 7.0
Median (range) 10 (0–29)
BMI, Body mass index; CAT, Chronic obstructive pulmonary disease assessment
test; FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity;
GOLD, Global Initiative on Obstructive Lung Disease; mMRC, Modified Medical
Research Council; SD, Standard deviation.
Table 2 Pulse oximetry monitoring results in
ex-/non-smokers (n = 39)
Daytime Nighttime
Monitoring duration (hours)
Mean ± SD 14.5 ± 3.7 8.5 ± 3.0
Proportion of SpO2 values < 90% (%)
Mean ± SD 3.0 ± 5.5 7.4 ± 16.1
Median (range) 1.1 (0.0–28.1) 1.3 (0.0–87.3)
Mean SpO2 (%)
Mean ± SD 94.7 ± 1.2 93.7 ± 1.8
Median (range) 94.9 (90.7–97.4) 93.9 (88.8–96.8)
Heart rate (beats/min)
Mean ± SD 76.9 ± 10.6 69.0 ± 9.0
Median (range) 75.0 (49.4–101.0) 68.2 (49.4–87.1)
SD, Standard deviation; SpO2, Oxygen saturation by pulse oximetry.
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night, and all other periods were defined as day. Patients
were encouraged to perform all normal daily ambulatory
activities, and to maintain their baseline levels of activity.
The daytime and nighttime mean SpO2 value, proportion
of SpO2 values below 90%, and heart rate were analysed.
The 3% oxygen desaturation index (3%ODI) during the
night was measured to detect patients with possible
obstructive sleep apnoea (OSA) [9].
Patients were followed up for as long as possible after
their ambulatory oximetry monitoring, and exacerba-
tions and survival were analysed. Exacerbations were re-
corded from the day of oximetry monitoring. Follow-up
ended on 30 November 2013. Exacerbation was defined
as an increase in respiratory symptoms lasting at least
3 days and requiring treatment with antibiotics or
systemic steroids.
The primary outcome was the proportion of desatura-
tors, defined by Levi-Valensi et al. as patients with ≥ 30%
of SpO2 values below 90% [10]. This definition was vali-
dated by Casanova et al. [11] and has also been used in
other recent studies of 24-hour or daytime oximetry
monitoring [3,5,12]. The secondary outcomes were the
mean SpO2, heart rate and occurrence of exacerbation.
Based on the results of previous studies [3,11], the pro-
portion of desaturators was estimated to be approxi-
mately 24% in COPD patients with a resting PaO2 of
60–70 mmHg. The proportion of desaturators in this
study was estimated to be 8%, because we expected the
study to include a higher proportion of patients with
mild COPD than previous studies. For a one-sided alpha
of 5% and a power of 80%, we estimated that 47 evalu-
able subjects would be needed. Given the possibility of
incomplete data in some patients, we considered that 50
subjects would be needed for this study. The study was
approved by the Osaka Police Hospital ethics committee.
All patients provided written informed consent for
inclusion in the study.
Data analysis
The values for normally distributed continuous variables,
discrete variables, and categorical variables are expressed
as the mean ± standard deviation (SD), median (range),
and frequency, respectively. Comparisons between groups
were performed using the unpaired t-test for normally dis-
tributed continuous variables. Simple and multiple regres-
sion analyses were performed to evaluate relationships
between variables and the proportion of daytime SpO2
values below 90%. The following factors were included in
the simple regression analyses: percent predicted FEV1 (%
FEV1), mMRC dyspnoea grade, CAT score, resting PaO2,
resting PaCO2, body mass index (BMI), and age. All vari-
ables with a p value of < 0.2 on univariate analysis were
included in the multiple regression analysis. The multiple
Table 3 Characteristics of exacerbations in
ex-/non-smokers (n = 39)
Follow-up duration
(months)
Mean ± SD 26.4 ± 6.7
Median (range) 27.8 (4.1–32.8)




Antibiotic use Total uses/patients 15/10
Systemic steroid use Total uses/patients 4/4
SD, Standard deviation.
Minami et al. Multidisciplinary Respiratory Medicine 2014, 9:24 Page 4 of 8
http://www.mrmjournal.com/content/9/1/24regression analysis results are expressed as the unstan-
dardized regression coefficient (β) with the corresponding
95% confidence interval, and the coefficient of determin-
ation (R2). Univariate and multivariate Cox proportional
hazards models were used to evaluate relationships
between the variables and exacerbation. The following
factors were included in the multivariate analysis: age-
adjusted Charlson Comorbidity Index [13], BMI, %FEV1,
and proportion of SpO2 values below 90% during the day
and night. The Cox proportional hazards analysis results
are expressed as risk ratio (RR) with the 95% confidence
interval. A two-tailed p value of < 0.05 was considered
statistically significant. Statistical analyses were performed
using StatMate statistical software (StatMate version IV;
ATMS Co., Ltd., Tokyo, Japan). The sample calculation
was performed using EZR (Saitama Medical Centre,
Jichi Medical University, Saitama City, Japan), a graph-
ical user interface for R (The R Foundation for Statis-
tical Computing) [14]. EZR is a modified version of R
commander designed to add statistical functions and
frequently used in biostatistics.Figure 1 Kaplan–Meier curves for exacerbation of COPD in 39 ex-/nonResults
A total of 51 Japanese patients were enrolled in the study
from February 2011 to September 2011. Thirty-eight pa-
tients were ex-smokers, 12 were current smokers, and 1
was a non-smoker who had been chronically exposed to
excessive environmental tobacco smoke. We excluded the
12 current smokers from our analyses, because smoking
status was not considered at study entry and some current
smokers were unexpectedly included. Current smoking
may increase SpO2 values due to a high serum carboxy-
haemoglobin (COHb) concentration [15-17]. The charac-
teristics of the ex-/non-smokers are shown in Table 1.
The daytime and nighttime oximetry monitoring results
are shown in Table 2. There were no daytime desaturators
and three nighttime desaturators. Although we did not con-
firm OSA by polysomnography, the results showed possible
OSA (3%ODI of more than 15 desaturations/hour) in six
patients [9]. Comparison of these 6 patients with the
remaining 33 patients found no significant differences in
the proportion of SpO2 values below 90% in the daytime
(1.7 ± 2.1 vs 3.2 ± 6.0%, p = 0.28) or nighttime (15.4 ± 9.9
vs 5.9 ± 17.0%, p = 0.08) or in the mean daytime SpO2
value (94.6 ± 0.8 vs 94.7 ± 1.3%, p = 0.86), but did find a
significant difference in the mean nighttime SpO2 value
(92.3 ± 0.9 vs 93.9 ± 1.8%, p = 0.03). In the nine patients
with a resting PaO2 of 60–70 mmHg (resting PaO2 66.2 ±
2.8 mmHg), including no daytime and two nighttime
desaturators, the proportion of SpO2 values below 90%
was 8.4 ± 9.0% during the day and 20.2 ± 28.5% during the
night, and the 3%ODI was more than 15 desaturations/
hour in one ex-smoker (15.6 desaturations/hour).
Simple regression analysis showed that higher %FEV1
(β = −0.12, p = 0.01), higher PaO2 (β = −0.30, p = 0.002)
and lower mMRC dyspnoea grade (β = 2.38, p = 0.002)-smokers (blue line).
Table 5 Multivariate Cox proportional hazards analysis of
relationships between variables and exacerbation in
ex-/non-smokers (n = 39)
Variable Risk ratio 95% CI p
Age-adjusted Charlson Comorbidity
Index
0.96 0.67 – 1.37 0.82
Body mass index 0.88 0.72 – 1.06 0.18
CAT score 1.08 0.99 – 1.18 0.10
%FEV1 0.99 0.95 – 1.02 0.45
Daytime proportion of SpO2
values < 90%
1.00 0.84 – 1.18 0.97
Nighttime proportion of SpO2
values < 90%
0.99 0.92 – 1.05 0.68
CAT, Chronic obstructive pulmonary disease assessment test; CI, confidence
interval; FEV1, forced expiratory volume in one second; SpO2, Oxygen
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daytime SpO2 values below 90% (Additional file 1: Data
1). Multivariate analysis identified only PaO2 as a signifi-
cant predictor of the proportion of daytime SpO2 values
below 90% (β = −0.21, p = 0.04) (Additional file 1: Data 2).
Five ex-smokers were lost to follow-up. Two ex-
smokers died of acute heart failure and unknown cause,
respectively. Thirty-two ex-/non-smokers were alive and
still followed up at the time of data cut-off. One third of
the patients experienced exacerbations during the follow-
up period (Table 3). The median time from oximetry
monitoring to the first exacerbation was not reached
(Figure 1). Univariate (Table 4) and multivariate (Table 5)
analyses did not detect any factors that were significantly
associated with exacerbation.saturation by pulse oximetry.Discussion
This study of Japanese COPD outpatients not receiving
supplemental oxygen therapy included no daytime desa-
turators and few nighttime desaturators. The propor-
tions of daytime and nighttime SpO2 values below 90%
did not predict exacerbation.Table 4 Univariate Cox proportional hazards analysis of
relationships between variables and exacerbation in
ex-/non-smokers (n = 39)
Variable Risk ratio 95% CI p
Age (years) 1.04 0.97 – 1.10 0.26
Unadjusted Charlson Comorbidity
Index
0.93 0.57 – 1.51 0.76
Age-adjusted Charlson Comorbidity
Index
1.06 0.76 – 1.46 0.74
Pack/years 1.00 0.98 – 1.01 0.69
Body mass index 0.87 0.73 – 1.03 0.10
mMRC dyspnoea grade 1.19 0.73 – 1.96 0.49
CAT score 1.08 1.00 – 1.16 0.054
PaO2 0.97 0.92 – 1.03 0.35
PaCO2 0.95 0.84 – 1.08 0.45
FEV1 0.60 0.23 – 1.53 0.28
%FEV1 0.99 0.96 – 1.02 0.45
Daytime
Proportion of SpO2 values < 90% (%) 1.01 0.92 – 1.11 0.78
Mean heart rate 1.02 0.97 – 1.07 0.42
Nighttime
Proportion of SpO2 values < 90% 0.98 0.92 – 1.03 0.41
3%ODI 0.92 0.82 – 1.02 0.12
Mean heart rate 1.01 0.95 – 1.07 0.71
CAT, Chronic obstructive pulmonary disease assessment test; CI, Confidence
interval; FEV1, Forced expiratory volume in one second; mMRC, Modified
Medical Research Council; ODI, Oxygen desaturation index; PaCO2, Partial
pressure of arterial carbon dioxide; PaO2, Partial pressure of arterial oxygen;
SpO2, Oxygen saturation by pulse oximetry.To the best of our knowledge, only four previous stud-
ies have reported the results of continuous 24-hour oxy-
gen saturation monitoring during activities of daily living
using a portable pulse oximeter (Table 6) [3,5,11,18]. The
population of the present study differed from the popula-
tions of these previous studies in terms of race, disease
severity (%FEV1 and resting PaO2), physique (BMI), and
SpO2 values. Patients with more severe COPD generally
tend to be more underweight [19-21]. However, the pa-
tients in this study had milder COPD but were more
underweight than patients in previous non-Asian studies.
Additionally, our oximetry results were much better than
in previous studies. Patients in this study had less frequent
daytime and nighttime desaturations than those in the
previous studies. Although even the nine patients with a
resting PaO2 of 60–70 mmHg had better oxygen satur-
ation profiles than patients in the previous non-Asian
studies, their desaturation profiles and pulmonary func-
tion were comparable to those of the 55 non-desaturators
in the study by Casanova et al., which also found that
non-desaturators were less hypercapnic and less hypox-
emic during the daytime than desaturators in spite of
having similar pulmonary function and Saint George’s
Respiratory Questionnaire scores [11]. Our nine patients
with a resting PaO2 of 60–70 mmHg had lower resting
PaCO2 values than patients in the previous studies. These
comparisons suggest that desaturators are likely to have
hypercapnic respiratory failure.
In this study, oximetry results did not predict exacerba-
tion. This is consistent with the findings of Trauer et al.,
who reported that ambulatory oximetry results in patients
with a resting PaO2 of 56–70 mmHg did not predict
exacerbation or survival [12]. They proposed four reasons
for the lack of association between oximetry results and
survival: 1) oximetry results are not fundamentally impor-
tant for predicting prognosis, 2) progression of COPD is
unpredictably heterogeneous, 3) the sample size was not




















30 inpts Not defined 3 Patients* Median (range) Median (range) Median (range) Not described Not described




88 outpts 60–70 mmHg None Mean ± SD Mean ± SD Mean ± SD Daytime 22% Non-desaturators
64.7 ± 2.8 38 ± 13 27 ± 4 Nighttime 50% 24-hour 12.2%








67 outpts 60–70 mmHg None Median (range) Median (range) Not described 24-hour 30% 24-hour 17%
66 (60–70) 37 (16–64) Daytime 25% Daytime 15%
45 (32–57) Nighttime 45% Nighttime 23%
Trauer (2012) [5] 35 outpts 56–70 mmHg None Mean ± SD Mean ± SD Mean ± SD 24-hour 54% 24-hour 41.9%
64.1 ± 4.5 37.5 ± 13.2 27.1 ± 7.0 Daytime 40% Daytime 30.9%
44.2 ± 6.0 Nighttime 77% Nighttime 60.6%
This study 39 outpts Not defined None Mean ± SD Mean ± SD Mean ± SD Daytime 0% Daytime 3.0%
78.2 ± 8.9 50.9 ± 18.5 23.1 ± 3.8 Nighttime 8% Nighttime 7.4%
39.1 ± 4.9
9 outpts** 60–70 mmHg None 66.2 ± 3.0 37.0 ± 14.6 23.9 ± 4.8 Daytime 0% Daytime 8.4%
38.0 ± 5.4 Nighttime 22% Nighttime 20.2%
*Three patients had not previously received supplemental oxygen therapy, but started nocturnal oxygen therapy during admission to a pulmonary
rehabilitation programme.
**Nine patients in this study had more severe COPD with mild-to-moderate hypoxaemia (PaO2 60–70 mmHg).
BMI, body mass index; FEV1, Forced expiratory volume in one second; Inpts, inpatients; Outpts, outpatients; PaO2, partial pressure of arterial oxygen; Ref,
Reference; SD, Standard deviation; SpO2, Oxygen saturation by pulse oximetry.
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oxygen saturation reflected greater levels of physical acti-
vity. In the present study, the lack of association between
oximetry results and the risk of exacerbation may be
related to the small sample size, as the patients had mild
COPD and therefore had lower rates of exacerbation and
death than in the study by Trauer et al. [12]. However, the
CAT score may be an independent predictor of exacerba-
tion, as also recently reported in other studies [22,23].
This study has some limitations. First, despite using an
activity log, it was not possible to accurately determine
the patients’ physical activities at specific times. It is
difficult for patients to accurately record activities by the
minute, or accurately recall activities over longer periods
of time [24]. Most patients in this study had inaccurate
recordings, and patients frequently forgot to record any
activities at all. The resulting activity logs were not useful
for comparison with pulse oximetry results. It has been
reported that patients with COPD are markedly inactivein daily life [25], and that the reduction in physical activity
starts in the early stages of the disease, even before COPD
is diagnosed [26]. It is therefore possible that the minimal
desaturations recorded in this study reflected reduced ac-
tivity levels. Use of motion sensors such as accelerometers
seems to be a promising alternative to patient-reported ac-
tivity logs. Only one previous study reported concomitant
measurement of SpO2 and physical activity by oximeter,
accelerometry and actigraphy, respectively [27]. However,
the analysis in this study divided activities into only four
categories: walking, slow-intermittent-walking, active-not-
walking, and resting. These broad classifications are not
sufficient for linking desaturation profiles with activities of
daily living. Second, the influence of COHb on SpO2
values in the 12 current smokers was not assessed, be-
cause the COHb concentrations were not measured.
Therefore, we excluded the current smokers from our
analyses, and it remains unknown whether ambulatory
oximetry monitoring is reliable in smokers. Finally,
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previous studies. Only the study by Casanova et al. re-
ported repeat 24-hour oximetry monitoring, at 1–3 weeks
after the initial monitoring in 11 patients [11]. They did
not find significant differences between the results of the
two monitoring periods. Although it is necessary to inves-
tigate whether a single 24-hour monitoring period is
sufficient for evaluation of the desaturation profile, it is
difficult to perform monitoring over multiple periods be-
cause of patient discomfort and disturbance of activities of
daily living while the monitor is attached.Conclusions
Our 24-hour ambulatory oximetry monitoring provided
precise data regarding the desaturation profiles of Japanese
outpatients with COPD. Both daytime and nighttime desa-
turations were infrequent. The proportion of SpO2 values
below 90% did not predict exacerbation of COPD.Availability of supporting data
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